Delivery Order SPE2DB22D2006-SPE2DB25FW3YM
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,634.27 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price, competitively awarded delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $35,697.41 by the Defense Logistics Agency for REPATHA 140 mg/ml SureClick auto-injector medication. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025, under a firm fixed-price delivery order structure with no set-aside designation. This competitive award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,201.32 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pharmaceutical product, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,254.40 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,393.01 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 MG/ML SureClick auto-injectors. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was made under a competitive procurement process, reflecting AmerisourceBergen's capability to meet federal pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,092.35 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This non-set-aside, firm fixed price contract was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $55,027.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on August 20, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3YMDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,081.08 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract employs firm fixed price pricing and carries an ultimate completion date of September 3, 2025, with performance to be executed at the contractor's Conshohocken, PA facility. This delivery order represents a non-competitive, non-set-aside award issued as a child contract under a larger vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.9 million through December 2026. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. REPATHA, a cholesterol-reducing medication for cardiovascular disease management, represents the type of specialized pharmaceutical product the contractor regularly delivers through its DLA contract portfolio to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/2/25 |